$FENC
FENNEC PHARMACEUTICALS INC.

2016 Q2 Form 10-Q Financial Statement

#000114420416118605 Filed on August 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $570.0K $410.0K $500.0K
YoY Change 14.0% 0.0% -41.86%
% of Gross Profit
Research & Development $139.0K $47.00K $54.00K
YoY Change 157.41% 9.3% -25.0%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $139.0K $47.00K $54.00K
YoY Change 157.41% 9.3% -25.0%
Operating Profit -$707.0K -$454.0K
YoY Change 0.44%
Interest Expense -$10.00K $30.00K $390.0K
YoY Change -102.56% -95.24%
% of Operating Profit
Other Income/Expense, Net -$17.00K $34.00K $376.0K
YoY Change -104.52% -94.59% 108.89%
Pretax Income -$720.0K -$420.0K -$170.0K
YoY Change 323.53% -333.33% -77.33%
Income Tax
% Of Pretax Income
Net Earnings -$724.0K -$420.0K -$173.0K
YoY Change 318.5% -337.29% -76.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06 -$0.04 -$0.02
Diluted Earnings Per Share -$0.06 -$0.04 -$0.02
COMMON SHARES
Basic Shares Outstanding 10.94M shares 10.83M shares
Diluted Shares Outstanding 10.94M shares 10.83M shares

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.080M $550.0K $1.850M
YoY Change 174.59% -71.35% 81.37%
Cash & Equivalents $5.081M $545.0K $1.854M
Short-Term Investments
Other Short-Term Assets $30.00K $40.00K $10.00K
YoY Change 200.0% 1900.0% -75.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.100M $590.0K $1.870M
YoY Change 172.73% -69.74% 78.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $5.100M $590.0K $1.870M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $5.100M $590.0K $1.870M
YoY Change 172.73% -69.73% 78.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $350.0K $230.0K $400.0K
YoY Change -12.5% -40.1% 17.65%
Accrued Expenses $50.00K $80.00K $50.00K
YoY Change 0.0% 77.78% 25.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $450.0K $350.0K $760.0K
YoY Change -40.79% -68.83% -86.69%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $450.0K $350.0K $760.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $450.0K $350.0K $760.0K
YoY Change -40.79% -68.83% -86.69%
SHAREHOLDERS EQUITY
Retained Earnings $113.2M -$112.0M
YoY Change 1.13%
Common Stock $111.0M
YoY Change 0.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.653M $243.0K $1.112M
YoY Change
Total Liabilities & Shareholders Equity $5.100M $588.0K $1.870M
YoY Change 172.73% -69.83% 78.1%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q2
OPERATING ACTIVITIES
Net Income -$724.0K -$420.0K -$173.0K
YoY Change 318.5% -337.29% -76.93%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$470.0K -$500.0K -$511.0K
YoY Change -8.02% 19.05% 24.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $102.0K
YoY Change 277.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.010M 100.0K $449.0K
YoY Change 1015.81% 270.37% 416.09%
NET CHANGE
Cash From Operating Activities -470.0K -500.0K -$511.0K
Cash From Investing Activities 0.000 0.000 $0.00
Cash From Financing Activities 5.010M 100.0K $449.0K
Net Change In Cash 4.540M -400.0K -$62.00K
YoY Change -7422.58% -1581.48% -80.8%
FREE CASH FLOW
Cash From Operating Activities -$470.0K -$500.0K -$511.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1005000 USD
us-gaap Net Income Loss
NetIncomeLoss
-1144000 USD
us-gaap Net Income Loss
NetIncomeLoss
4000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
186000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97000 USD
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
376000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-724000 USD
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-173000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139000 USD
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
545000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5006000 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
449000 USD
CY2016Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6000 USD
CY2015Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
449000 USD
CY2016Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
5081000 USD
CY2015Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
942000 USD
CY2016Q2 us-gaap Cash
Cash
231000 CAD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.1
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2235000 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2015Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-969000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-929000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5108000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
476000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-58000 USD
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-34000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-14000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
48000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
93000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-42000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-83000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
108000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
476000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-470000 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-511000 USD
CY2016Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2016Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2016Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4536000 USD
CY2016Q2 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-22000 USD
CY2015Q2 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-17000 USD
CY2016Q2 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2000 USD
CY2015Q2 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1000 USD
CY2016Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
120000 USD
CY2015Q2 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
17000 USD
CY2016Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-31000 USD
CY2015Q2 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4000 USD
CY2015Q4 fencf Stock Options Issuance
StockOptionsIssuance
65000 shares
CY2016Q2 fencf Stock Options Issuance
StockOptionsIssuance
40000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000 USD
CY2016Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
fencf Stock Options Issuance Exercised
StockOptionsIssuanceExercised
14000 shares
fencf Stock Options Issuance Forfeited
StockOptionsIssuanceForfeited
11000 shares
fencf Stock Options Issuance Expired
StockOptionsIssuanceExpired
0 shares
CY2015Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber
0 shares
CY2016Q2 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0 shares
fencf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
0 USD
us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
0 USD
us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
111000 USD
us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
19000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
111000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
19000 USD
CY2016Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
0 USD
CY2015Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Capitalized Cost
ShareBasedGoodsAndNonemployeeServicesTransactionCapitalizedCost
0 USD
CY2016Q2 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
111000 USD
CY2015Q2 us-gaap Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
10000 USD
CY2016Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
111000 USD
CY2015Q2 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
10000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000 USD
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.39 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0151 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.37 pure
CY2016Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
5081000 USD
CY2016Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
56000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
3000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001211583
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
FENCF
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13642567 shares
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13643000 shares
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13643000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10920000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10920000 shares
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000 USD
CY2015Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2000 USD
CY2016Q2 us-gaap Cash
Cash
94000 USD
CY2015Q4 us-gaap Cash
Cash
11000 USD
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Use of estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and the reported amounts of expense during the reporting period.&#160;Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the opinion of management, these unaudited interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary for the fair presentation of the Company&#8217;s financial position at June 30, 2016 and to state fairly the results for the periods presented. The most significant estimates utilized during the quarter ended June 30, 2016 included estimates necessary to value derivative instruments, disclosed in Note 4.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-123000 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-540000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-420000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
826000 USD
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
1112000 USD
CY2015Q3 us-gaap Stockholders Equity
StockholdersEquity
1019000 USD
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
243000 USD
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1700000 shares
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2016Q2 fencf Proceeds From Issuance Of Rights Offering
ProceedsFromIssuanceOfRightsOffering
5000000 USD
CY2015Q2 fencf Proceeds From Issuance Of Rights Offering
ProceedsFromIssuanceOfRightsOffering
0 USD
fencf Proceeds From Issuance Of Rights Offering
ProceedsFromIssuanceOfRightsOffering
5000000 USD
fencf Proceeds From Issuance Of Rights Offering
ProceedsFromIssuanceOfRightsOffering
0 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
613000 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9000 USD
CY2015Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
10000 USD
CY2015Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
9000 USD
CY2015Q4 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
69000 USD
CY2016Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
111000 USD
CY2015Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000 USD
CY2015Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 USD
CY2016Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
177000 USD
CY2015Q2 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
449000 USD
CY2016Q1 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
102000 USD
CY2016Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13000 USD
CY2016Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
17000 USD
CY2016Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000 USD
CY2015Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.82
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2016Q2 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
1.81

Files In Submission

Name View Source Status
0001144204-16-118605-index-headers.html Edgar Link pending
0001144204-16-118605-index.html Edgar Link pending
0001144204-16-118605.txt Edgar Link pending
0001144204-16-118605-xbrl.zip Edgar Link pending
fencf-20160630.xml Edgar Link completed
fencf-20160630.xsd Edgar Link pending
fencf-20160630_cal.xml Edgar Link unprocessable
fencf-20160630_def.xml Edgar Link unprocessable
fencf-20160630_lab.xml Edgar Link unprocessable
fencf-20160630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tex99-1logo.jpg Edgar Link pending
v445807_10q.htm Edgar Link pending
v445807_ex31-1.htm Edgar Link pending
v445807_ex31-2.htm Edgar Link pending
v445807_ex32-1.htm Edgar Link pending
v445807_ex99-1.htm Edgar Link pending